AT450547T - EML4-ALK fusion gene - Google Patents

EML4-ALK fusion gene

Info

Publication number
AT450547T
AT450547T AT07254044T AT07254044T AT450547T AT 450547 T AT450547 T AT 450547T AT 07254044 T AT07254044 T AT 07254044T AT 07254044 T AT07254044 T AT 07254044T AT 450547 T AT450547 T AT 450547T
Authority
AT
Austria
Prior art keywords
eml4
fusion gene
alk fusion
alk
gene
Prior art date
Application number
AT07254044T
Other languages
German (de)
Inventor
Hiroyuki Mano
Sadao Kuromitsu
Nobuaki Shindo
Takatoshi Soga
Takashi Furutani
Original Assignee
Astellas Pharma Inc
Curegene K K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2006277718 priority Critical
Priority to JP2007120670 priority
Priority to CA 2598893 priority patent/CA2598893C/en
Application filed by Astellas Pharma Inc, Curegene K K filed Critical Astellas Pharma Inc
Publication of AT450547T publication Critical patent/AT450547T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
AT07254044T 2006-10-11 2007-10-11 EML4-ALK fusion gene AT450547T (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2006277718 2006-10-11
JP2007120670 2007-05-01
CA 2598893 CA2598893C (en) 2006-10-11 2007-08-24 Eml4-alk fusion gene

Publications (1)

Publication Number Publication Date
AT450547T true AT450547T (en) 2009-12-15

Family

ID=39277176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07254044T AT450547T (en) 2006-10-11 2007-10-11 EML4-ALK fusion gene

Country Status (7)

Country Link
US (7) US7728120B2 (en)
EP (1) EP2116553B1 (en)
JP (2) JP4303303B2 (en)
AT (1) AT450547T (en)
CA (1) CA2598893C (en)
DE (1) DE602007003543D1 (en)
ES (2) ES2515170T3 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
DK2450437T3 (en) * 2006-04-14 2017-09-11 Cell Signaling Technology Inc Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
CN101466721B (en) * 2007-04-13 2013-08-21 细胞信号技术公司 Gene defect and mutant ALK kinase in human entity tumour
TWI389893B (en) * 2007-07-06 2013-03-21 Astellas Pharma Inc Di (arylamino) ary1 compound
JP2011511949A (en) * 2008-02-12 2011-04-14 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド FISH assay for fusion of EML4 and ALK in lung cancer
JP2009219728A (en) * 2008-03-18 2009-10-01 Daito Giken:Kk Game machine
BRPI0908637A2 (en) 2008-05-21 2018-10-23 Ariad Pharma Inc compound; pharmaceutical composition thereof and method for inhibiting cell proliferation in an individual.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2010132888A2 (en) * 2009-05-15 2010-11-18 Insight Genetics, Inc. Methods and compositions relating to fusions of alk for diagnosing and treating cancer
JPWO2011043220A1 (en) 2009-10-06 2013-03-04 富士レビオ株式会社 Measurement method of fusion gene
WO2011087709A2 (en) 2009-12-22 2011-07-21 Quest Diagnostics Investments Incorporated Eml4-alk translocations in lung cancer
US9157905B2 (en) 2010-02-22 2015-10-13 Fujirebio Inc. Method for identifying oncogene, method for establishing oncogene-expressing cell, and method of screening oncogene targeting drug
US8383793B2 (en) 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
TW201202703A (en) * 2010-04-16 2012-01-16 Response Genetics Inc Primers, probes, methods, and kits for the detection of EML4-ALK variants
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
CN103052386B (en) 2010-08-20 2016-03-02 中外制药株式会社 Compositions containing tetracyclic compound
US8962245B2 (en) 2010-09-02 2015-02-24 Kurume University Method for producing circular DNA formed from single-molecule DNA
JP2014005206A (en) * 2010-10-22 2014-01-16 Astellas Pharma Inc Arylamino heterocyclic carboxamide compound
JP5769952B2 (en) * 2010-11-12 2015-08-26 株式会社Lsiメディエンス Highly sensitive detection method for EML4-ALK fusion gene
WO2012075318A2 (en) * 2010-12-01 2012-06-07 Cell Signaling Technology, Inc. Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
JP5837095B2 (en) * 2011-02-02 2015-12-24 アイアールエム・リミテッド・ライアビリティ・カンパニーIrm,Llc How to use an ALK inhibitor
WO2012139134A2 (en) * 2011-04-07 2012-10-11 Coferon, Inc. Methods of modulating oncogenic fusion proteins
MX360404B (en) 2011-05-04 2018-10-31 Ariad Pharma Inc Compounds for inhibiting cell proliferation in egfr-driven cancers.
EP2752486B1 (en) * 2011-08-31 2016-12-28 Kurume University Method for exclusive selection of circularized dna from monomolecular dna when circularizing dna molecules
EP2838998B1 (en) 2012-04-18 2017-10-11 Cell Signaling Technology, Inc. Egfr and ros1 in cancer
JP6469567B2 (en) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
JP2016510316A (en) * 2012-12-21 2016-04-07 エピザイム,インコーポレイティド DOT1L inhibitor for use in the treatment of leukemia
WO2014128235A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
JPWO2015064620A1 (en) * 2013-10-29 2017-03-09 公益財団法人がん研究会 Novel fusion and detection method thereof
WO2015064621A1 (en) * 2013-10-29 2015-05-07 公益財団法人がん研究会 Novel fusions and detection method therefor
WO2015111716A1 (en) 2014-01-24 2015-07-30 公益財団法人がん研究会 Novel fusant and method for detecting same
EP3135671B1 (en) 2014-04-25 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Novel crystal of tetracyclic compound
US10350214B2 (en) 2014-04-25 2019-07-16 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
TW201613906A (en) 2014-08-08 2016-04-16 Chugai Pharmaceutical Co Ltd Amorphous body of tetracyclic compound
US20160097103A1 (en) * 2014-09-01 2016-04-07 Arkray, Inc. Primer reagent for amplifying ALK fusion gene, ALK fusion gene amplification reagent kit including the same, and ALK fusion gene amplification method and ALK fusion gene analysis method using the same
JP2017163992A (en) * 2017-05-02 2017-09-21 セル・シグナリング・テクノロジー・インコーポレイテツド Gene defect and mutant alk kinase in human solid tumor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338210T3 (en) 1999-11-11 2010-05-05 Astellas Pharma Inc. New metaloprotease that has agrecanase activity.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
SI1660458T1 (en) 2003-08-15 2012-05-31 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
EP1730128A1 (en) 2004-03-31 2006-12-13 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
CN101466721B (en) 2007-04-13 2013-08-21 细胞信号技术公司 Gene defect and mutant ALK kinase in human entity tumour
TWI389893B (en) 2007-07-06 2013-03-21 Astellas Pharma Inc Di (arylamino) ary1 compound

Also Published As

Publication number Publication date
EP2116553A1 (en) 2009-11-11
US20150184161A1 (en) 2015-07-02
ES2335368T3 (en) 2010-03-25
US7605131B2 (en) 2009-10-20
US20180066266A1 (en) 2018-03-08
US7964710B2 (en) 2011-06-21
CA2598893A1 (en) 2008-04-11
US9029521B2 (en) 2015-05-12
US20080090776A1 (en) 2008-04-17
US9932589B2 (en) 2018-04-03
US20090099193A1 (en) 2009-04-16
JP5172736B2 (en) 2013-03-27
US20110230545A1 (en) 2011-09-22
DE602007003543D1 (en) 2010-01-14
US8197818B2 (en) 2012-06-12
ES2515170T3 (en) 2014-10-29
US7728120B2 (en) 2010-06-01
JP2008295444A (en) 2008-12-11
EP2116553B1 (en) 2014-07-30
US20130158095A1 (en) 2013-06-20
CA2598893C (en) 2012-04-10
JP4303303B2 (en) 2009-07-29
JP2009100783A (en) 2009-05-14
US20100240673A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
DK2096917T3 (en) Cyclopamine-ANALOGS
DK1859712T3 (en) Kapselperforeringsmodul
DK2091663T3 (en) Ultralydsvæskeforstøver
DK2069312T3 (en) pyridazinone
AT540395T (en) Anzeigeansteuersysteme
NL300919I2 (en) Brodalumab
AT465907T (en) Verschlusskappe
AT451067T (en) Elektrodeneinführeinrichtung
AT474514T (en) Schienbeinkopfausgleichsosteotomieplatte
AT443753T (en) Nuancierungsmittel
DE602007012238D1 (en) Years
DE502007007057D1 (en) Wischblatt
DE602007013009D1 (en) Esh-networks
AT539748T (en) glucokinase
AT475662T (en) Dihydropyrazolopyrimidinonderivate
AT489973T (en) Hydrogen-atomizers
AT477312T (en) Flüssigkeitshärtung
AT530853T (en) Strahlrohrbratrost
DE602007013937D1 (en) torantagonisten
AT546501T (en) Bördelfalzverklebung
DE602007013853D1 (en) Mageninvaginationsvorrichtung
DE602007008851D1 (en) ektionsmittel
AT483916T (en) Axialgebläseanordnung
AT461621T (en) Hundepriem
AT483711T (en) Spiroindolinonderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties